OncRef

Clinical Trial: NCT04547504

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:University Hospital, Brest
Information Provided By:University Hospital, Brest
Last Update Posted:2025-09-17

Study Overview

Brief Summary

PERSEE is a French national phase 3 academic study comparing the chemotherapy-pembrolizumab combination to pembrolizumab alone as a first-line treatment for advanced NSCLC molecularly defined by a PDL1 expression ≥ 50% of tumour cells and no EGFR mutations or ALK rearrangement.

The main hypothesis is the superiority of the chemo-immunotherapy combination over mono-immunotherapy in terms of progression-free survival evaluated by an independent review committee.

One of the anticipated benefits of using the chemotherapy-pembrolizumab combination starting from the first line setting for NSCLC patients with PD L1 ≥ 50% is a reduced risk of early progression, which is known to occur with pembrolizumab monotherapy, and therefore, a better PFS.

Official Title

Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%

Conditions

Non-small-cell Lung Cancer

Intervention / Treatment

  • Drug: Pembrolizumab
  • Drug: Pembrolizumab and Chemotherapy drugs

Other Study ID Numbers

  • 29BRC20.0159_GFPC01-2020
  • GFPC 01-2020

Start Date (Actual)

2020-12-22

Primary Completion Date (Estimated)

2025-12-22

Study Completion Date (Estimated)

2025-12-22

Enrollment (Actual)

349

Study Type

Interventional

Phase

Phase 3